Technical Analysis for FPRX - Five Prime Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 13.07 -3.97% -0.54
FPRX closed down 3.97 percent on Friday, March 22, 2019, on 1.44 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Up
See historical FPRX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Crossed Above 200 DMA Bullish -3.97%
Mar 21 Upper Bollinger Band Walk Strength -3.97%
Mar 21 Inside Day Range Contraction -3.97%
Mar 21 Above Upper BB Strength -3.97%
Mar 21 Overbought Stochastic Strength -3.97%
Mar 21 Upper Bollinger Band Touch Strength -3.97%

Older signals for FPRX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company's product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
Biotechnology Cancer Life Sciences Solid Tumors Monoclonal Antibodies Tyrosine Kinase Receptors Pfizer Gastric Cancer Glaxosmithkline Inflammatory Disease
Is FPRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.95
52 Week Low 7.84
Average Volume 264,663
200-Day Moving Average 13.1233
50-Day Moving Average 11.4936
20-Day Moving Average 12.1405
10-Day Moving Average 12.572
Average True Range 0.592
ADX 37.17
+DI 31.38
-DI 8.4274
Chandelier Exit (Long, 3 ATRs ) 11.944
Chandelier Exit (Short, 3 ATRs ) 12.586
Upper Bollinger Band 13.6377
Lower Bollinger Band 10.6433
Percent B (%b) 0.81
BandWidth 24.664553
MACD Line 0.4792
MACD Signal Line 0.3367
MACD Histogram 0.1425
Fundamentals Value
Market Cap 367.01 Million
Num Shares 28.1 Million
EPS -4.26
Price-to-Earnings (P/E) Ratio -3.07
Price-to-Sales 37.28
Price-to-Book 3.79
PEG Ratio 0.14
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.06
Resistance 3 (R3) 14.17 13.94 13.90
Resistance 2 (R2) 13.94 13.69 13.89 13.84
Resistance 1 (R1) 13.51 13.54 13.40 13.40 13.78
Pivot Point 13.28 13.28 13.23 13.23 13.28
Support 1 (S1) 12.85 13.03 12.74 12.74 12.36
Support 2 (S2) 12.62 12.88 12.57 12.30
Support 3 (S3) 12.19 12.62 12.25
Support 4 (S4) 12.08